Brodalumab: 5-Year US Pharmacovigilance Report

By sjmartinez • May 10, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb). 2024 May 9. doi: 10.1007/s13555-024-01162-8. Epub ahead of print. PMID: 38724839.

Tags: Adverse events, Dermatology, Drug reaction, psoriasis, Publications, real-world, safety

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison

Armstrong A, Kircik L, Metelitsa A, Warren RB, Rodriguez A, Volc S, Issa N, Chovatiya R, von Eyben R, Festini T, Johansen P, Ehst B.[...]

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement

Akiska YM, Fu J, Castelo-Soccio L, Mathes E, Mirmirani P, Jamerson T, Sibbald C; and The Pediatric Low-Dose Oral Minoxidil Consensus Expert Group; Spagnol Abraham[...]

Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply

Armstrong AW, Nong Y, Merola JF. Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply. JAMA Dermatol. 2026 Sep 23. doi: 10.1001/jamadermatol.2026.3645. Epub ahead of print.[...]